Core Viewpoint - PwC announced that Sichuan Ruijian Medical's financial statements are set to expire on December 31, 2024, leading the company to voluntarily suspend its subsequent listing review process with the Beijing Stock Exchange [1] Group 1 - Sichuan Ruijian Medical submitted an application to suspend its listing review process on September 26, 2025 [1] - The review status of the subsequent listing has been adjusted to "suspended" by the Beijing Stock Exchange [1] - On September 30, 2025, Sichuan Ruijian Medical received a second round inquiry letter regarding its public offering and listing application from the Beijing Stock Exchange [1] Group 2 - The subsequent listing and its review process have not been terminated, and related matters are still ongoing [1] - Sichuan Ruijian Medical's shares will continue to be suspended on the National Equities Exchange and Quotations system [1] - The company will issue further announcements in accordance with listing rules as necessary [1]
普华和顺：四川睿健医疗的其后上市的审核状态已由北京证券交易所相应调整为中止审核